| 09/27/2017 |
Year Ending March 31, 2018 Results of 2nd Quarter Settlement of Accounts Supplementary Material (Apr.1 to Sep.30 2017) |
| 09/27/2017 |
About Joint Promotion of Infliximab BS for I.V.Infusion 100mg ""Nichi-Iko"" |
| 09/27/2017 |
About Marketing Approval for Infliximab BS for I.V.Infusion 100mg ""AYUMI"" |
| 09/27/2017 |
About Marketing Approval for Infliximab BS for I.V.Infusion 100mg ""Nichi-Iko"" and the Status of Development in the U.S.A. |
| 09/08/2017 |
Consolidated Financial Results for the 1st Quarter of the Fiscal Year Ending March 31,2018 |
| 08/09/2017 |
Year Ending March 31, 2018 Results of 1st Quarter Settlement of Accounts Supplementary Material (Apr.1 to Jun.30 2017) |
| 07/14/2017 |
Licensing Agreement for Marketing Rights to Infliximab BS for I.V.Infusion 100mg ""AYUMI"" |
| 06/19/2017 |
Consolidated Financial Results for the Fiscal Year Ended March 31,2017 |
| 05/30/2017 |
Notice of the 53nd Ordinary General Meeting of Shareholders |
| 05/10/2017 |
Consolidated Financial Results for the Fiscal Year Ended March 31, 2017 Results Settlement of Accounts Supplementary Material (Apr.1 2016 to Mar.31 2017) |
| 02/28/2017 |
Consolidated Financial Results for the 3rd Quarter of the Fiscal Year Ending March 31,2017 |
| 02/08/2017 |
Year Ending March 31, 2017 Results of 3rd Quarter Settlement of Accounts Supplementary Material (Apr.1 to Dec.31 2016) |
